Peter Bercz, MD
Pulmonary Disease · Pensacola, FLNPI 1275725178
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,730 of the $14,179 with a category attached, or 61.6%. 40 manufacturers reported payments, led by Intuitive Surgical at 33.7% of the total. Reporting peaked in 2021 at $4,801 and has fallen 61.6% since, to $1,843 in 2025.
Across 449 payments — averaging $31.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$844
- GSK$817
- Veran Medical Technologies, Inc.$786
- Boehringer Ingelheim$680
- plus $5K from 34 others
Across 100 payments — averaging $13,249 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$516K
- Roche Molecular Systems, Inc.$326K
- Sanofi US Services Inc.$293K
- AstraZeneca$161K
- Boehringer Ingelheim$30K
- Janssen Research & Development, LLC$15
What the payments were for
- Travel & lodging$1,90513%
- Food & beverage$8,73062%
- Education$3,54425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,292
- Spin$786
- XYWAV$233
- BREZTRI$216
- Inspire$136
- HemoSphere$134
- TEZSPIRE$125
How this compares
$14,179 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 18 | $305,012 |
| AdempasRiociguat | 12 | $169,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $103,450 |
| Pirfenidone | 16 | $45,285 |
| Spiriva RespimatTiotropium Bromide | 51 | $34,991 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $32,482 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $30,972 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $25,520 |
| XareltoRivaroxaban | 16 | $12,891 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $12,291 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $9,590 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $8,500 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,356 |
| Ventolin HfaAlbuterol Sulfate | 60 | $4,418 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $604 | $305,01218 claims |
| BayerAdempas | $75 | $169,69712 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $817 | $155,213204 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $680 | $60,511101 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,421 | $39,83864 claims |
| Johnson & JohnsonXarelto | $38 | $12,89116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Pensacola
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.